For a rare genetic disorder, the difference between a prevalence estimate of 2.5 per million and 137 per million is not a rounding error — it is the difference between invisibility and a diagnosable population large enough to justify clinical trials, insurance coverage, and dedicated treatment pipelines. That gap is precisely what this new analysis of Phelan-McDermid syndrome (PMS) exposes.
PMS is a neurodevelopmental disorder caused by deletions or mutations affecting the SHANK3 gene on chromosome 22q13.3, and it is among the more tractable single-gene contributors to autism spectrum disorder. Prior prevalence estimates, based on limited ascertainment, placed PMS at 2.5 to 10 per million births. Pooling data from ten sources — including clinical genetic laboratories, research centers, and clinical programs — and evaluating records from 179,837 individuals with autism, the study calculated a weighted prevalence of 13.7 per 100,000 (95% CI: 10.02–18.60), equivalent to roughly 1 in 7,300 people. This estimate incorporated corrections for assay sensitivity differences across sites, the proportion of PMS individuals without autism, and age-of-diagnosis delays.
This finding carries significant downstream implications. Rare disease designations and orphan drug economics are built on prevalence thresholds; a 14-fold upward revision fundamentally changes the pharmacoeconomic calculus for developing SHANK3-targeted therapies, several of which are already in early-phase trials. The multisource capture-recapture-style methodology also provides a template for correcting ascertainment bias in other chromosomal syndromes that rely on autism registries for detection. Key limitations include the dependence on autism-ascertained cohorts as the primary entry point, which may still undercount individuals with PMS who present with intellectual disability or seizures without an autism diagnosis. The study is also observational and cross-sectional. Still, for a field where prevalence data drives research funding and newborn screening policy, this is a potentially paradigm-shifting recalibration.